• 312 days Will The ECB Continue To Hike Rates?
  • 312 days Forbes: Aramco Remains Largest Company In The Middle East
  • 314 days Caltech Scientists Succesfully Beam Back Solar Power From Space
  • 714 days Could Crypto Overtake Traditional Investment?
  • 719 days Americans Still Quitting Jobs At Record Pace
  • 721 days FinTech Startups Tapping VC Money for ‘Immigrant Banking’
  • 724 days Is The Dollar Too Strong?
  • 724 days Big Tech Disappoints Investors on Earnings Calls
  • 725 days Fear And Celebration On Twitter as Musk Takes The Reins
  • 727 days China Is Quietly Trying To Distance Itself From Russia
  • 727 days Tech and Internet Giants’ Earnings In Focus After Netflix’s Stinker
  • 731 days Crypto Investors Won Big In 2021
  • 731 days The ‘Metaverse’ Economy Could be Worth $13 Trillion By 2030
  • 732 days Food Prices Are Skyrocketing As Putin’s War Persists
  • 734 days Pentagon Resignations Illustrate Our ‘Commercial’ Defense Dilemma
  • 735 days US Banks Shrug off Nearly $15 Billion In Russian Write-Offs
  • 738 days Cannabis Stocks in Holding Pattern Despite Positive Momentum
  • 739 days Is Musk A Bastion Of Free Speech Or Will His Absolutist Stance Backfire?
  • 739 days Two ETFs That Could Hedge Against Extreme Market Volatility
  • 741 days Are NFTs About To Take Over Gaming?
David Craggen

David Craggen

Staff Writer, Safehaven.com

David Craggen is a financial analyst and writer for Safehaven.com

Contact Author

  1. Home
  2. News
  3. Breaking News

Smart Money Is Racing Into The Biotech Boom


The biotech boom is back.

After its big breakthrough a few years ago, the biotech industry fell silent.

Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs.

From exciting new technology to the FDA’s ‘fast-tracking’ of brand new therapies for a wide range of treatments, the biotech industry has once again found itself at exactly the right place at exactly the right time.

Before investing, however, it’s essential to know every detail about a company - and their particular niche.

Not only is the industry notorious for small companies exploding and then promptly losing it all, but it’s also on the cusp of brand new and potentially major breakthroughs…

Meaning that without the proper government green lights, even the most brilliant projects could be shut down in the blink of an eye. 

And with the industry growing faster than ever, it’s never been more important to stay ahead of these trends and regulations.

From industry giants like Microsoft to breakout start-ups like Champignon Brands (CN:SHRM;OTC:SHRMF) - the next great quantum physics or biotech boom is all about positioning yourself.

That’s why we’ve put together an outline of everything you need to know about one of the most exciting trends in the biotech sector as it expands in 2020.

An All Natural Solution

The secret to a successful biotech story lies in one thing: innovation.

Really making a dent in this market isn’t as easy as simply repacking an old idea…

It’s about seeing a solution for a problem no one else seems to be able to solve.

See, the world is experiencing a sort of mental health crisis. We’ve grown further apart than ever thanks to television, cellphones, and the internet. And we’ve lost touch with a lot of the things that used to bring us together.

As a result, mental health has become a global emergency.

And while traditional psychiatric medications are able to help most people...

Many people are still struggling.

For years, ‘fringe’ doctors and psychonauts have praised the benefits of a certain type of drug...

In fact, these all-natural therapies go back for centuries. 

Now, with the beginning of a wave of decriminalization taking place across the United States, psychedelics are targeting the center of a $13 billion medical boom.

And one little-known company called Champignon Brands (CN:SHRM;OTC:SHRMF) saw this trend coming and its stock has already tripled in value since March as they’ve got lots going for them.

First, they’ve got a vision. To bring help to a population who haven’t been able to benefit from Big Pharma’s traditional medicines.

In fact, they have a whole range of compounds that in clinical trials help everything from depression and anxiety to PTSD and alcoholism. 

While these highly praised medicines are still considered illegal, they’re starting to benefit from a new wave of acceptance across the United States and the globe.

See, the FDA just fast-tracked psilocybin, MDMA and ketamine for therapeutic research.

And the results in tests so far have been astounding. 

Champignon Brands saw this coming, in fact. That’s why they’ve been strategically positioning themselves for the next big biotech boom.

Unlike many companies in the biotech space, where investors expose themselves to massive risk in the hopes that a certain medical trial will pay off, Champignon Brands has an integrated vertical business model that provides it with a steady income to fund its groundbreaking medical trials.

Additionally, Champignon Brands (CN:SHRM;OTC:SHRMF) has an impressive acquisition list, buying up key companies in the industry in its determination to dominate this up and coming trend.

The Great CRISPR Debate

CRISPR is the technology at the center of one of the biggest debates in the scientific world. And it’s also one of the most fast-moving technologies in the scientific world.

Imagine how quickly computers went from giant boxes that took up entire rooms to little rectangles that fit in your pocket…

Now think about how that progression has impacted modern life.

A similar development is being worked on right now with CRISPR technology, a simple yet extremely powerful tool for editing genomes.

Gene-editing has unlocked a whole world of medical possibilities, like treating cancer or HIV. 

These are what are called therapeutic-somatic genetic modifications. But it’s slightly more complicated than that.

It also introduces the possibility of removing the genes that would essentially make a baby immune to those same diseases from the get-go. 

And while that’s already quite controversial, the debate really picks up when you consider the same technology could be used to make your future child taller, smarter, prettier or wittier.

It’s essentially pandora’s box - and science has just opened it. But there are some companies pursuing the technology responsibly.

Take CRISPR Therapeutics (NASDAQ:CRSP), for instance. Their research focuses entirely on the development of transformative gene-based medicine. 

Their treatments adhere to the current recommendations of the International Society for Stem Cell Research and target only somatic cells, which means their treatments will not be able to be transferred to a patient’s child.

Sangamo Therapeutics (NASDAQ:SGMO) is another diverse biotech player with a lot of promising treatments in its pipeline. 

From treatments for Huntington’s disease to Hemophilia, Sangamo is developing capabilities that allow them to design therapeutic approaches to resolve the underlying genetic causes of disease.

Quantum Computers

Quantum computing is going to transform the world as we know it.

From curing cancer to bringing an end to climate change, this is where the world’s biggest questions are being answered

Problems that we have previously considered ‘impossible’ could soon be solved in the click of a button. And breakthroughs are being made every day.

Just a few months ago, Google (NASDAQ:GOOG) claimed to have achieved the holy grail of quantum computing - quantum supremacy. It is something that scientists have been working on since the 1980s and, in late 2019, the Silicon Valley giant reported on this huge breakthrough.

So what does this breakthrough mean in laymen’s terms?

Well, the Google device completed a calculation that a supercomputer would take more than 10,000 years to complete… in 3 minutes and 20 seconds. 

It is a breakthrough that has been compared to the Wright brother’s first flight - proof of a concept that will likely change the world forever.

And it’s not the first time that Google has been at the forefront of quantum computing. In 2016, Google produced the first completely scalable quantum simulation of a hydrogen molecule. The implication of that breakthrough was equally enormous. If a quantum computer can accurately represent chemistry then it could, one-day, simulate and cure our worst health complications and diseases. 

Meanwhile, Microsoft’s (NASDAQ:MSFT) Quantum Lab in Sydney, Australia has developed the ability to control 50,000 qubits through three wires, a cryogenic CMOS design, and a 1cm2 chip computing at near absolute zero temperatures. 

In the words of the director of the Quantum Lab, it is “one of the most sophisticated micro-devices ever made” and its ability to work with any type of quantum computing hardware could change the entire industry. 

The next step for Microsoft now that they have this chip is to scale up the computer and begin solving real-world problems.

Arguably the most exciting problem out there is ending climate change. The idea, just like with Google’s hydrogen simulation, is to simulate large complex molecules and then uncover new catalysts for carbon capture that are cheap and hyper-efficient. 

Currently, we can simulate small molecules up to a few dozen qubits but need to scale this to the order of 1 million to solve these kinds of problems. Either of these computing giants could hold the key to the next great breakthrough - changing the world forever.

Other companies set to profit from the biotech boom:

Quintiles IMS Holdings, Inc (NYSE:Q) is one of the world’s “most admired companies” according to Fortune Magazine. Spanning over 100 countries, Quintiles IMS is definitely ahead of the pack. Quintiles IMS provides research and development solutions to pharmaceutical, biotech, and security industries that push healthcare forward using data and technology.   

Founded in 1982, it is safe to say that Quintiles IMS has been around the block a few times. The company’s strong management and forward-thinking attitude provide investors reassurance in a chaotic marketplace. As the world’s largest contract research organization, the company has key relationships throughout the global medical field, making it a strong bet for potential investors.

Veeva (NYSE:VEEV) Veeva is one of the most prominent cloud services providers out there, focusing specifically on the pharmaceutical sector. The company's cloud platform for the world's pharma companies is more popular than ever before.

After rallying to an all-time high in May, its share price has fallen a bit since. While its bigger brother ‘Salesforce’ has a stronger cash flow, Veeva has seen some healthy profits lately. Analysts now argue that the company might be ‘expensive’, but worth it. With an expected growth rate of 24% this year, it looks like investors will be rewarded for their patience.

By. Steve Everett


FORWARD-LOOKING STATEMENT. Statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Forward looking statements in this article include: that governments will legalize and regulate psychedelic medicine; that psychedelic medicine will provide effective treatment for mental health problems; and that Champignon’s business will be profitable. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information.   Matters that may affect the outcome of these forward looking statements include: that Psychedelic medicine may not be legalized on the timeline as expected or at all; that markets may not materialize as expected; that psychedelic medicine may not turn out to have as large a market as thought or be as lucrative as thought as a result of competition or other factors; that Champignon may not be as able to diversify or scale up  as thought because of potential lack of capital, lack of facilities, regulatory compliance requirements or lack of suitable employees, partners or suppliers; none of Champignon’s treatments have passed clinical trials or received FDA or other health authorities’ approval; that Champignon may not be able to raise funds and develop better treatments than competitors in the psychedelic medicine industry; that actual operating performance of the facilities Champignon do not meet expectations; that competition quickly develops; that Champignon may not be able to retain key employees, partners and suppliers; costs may be higher than expected and profits therefore lower; competitors may capture most or all of the increased market demand; and other risks affecting the Company in particular and the psychedelic medicine industry generally, including without limitation risks related to most agricultural crops, including crop failure and medical developments, including without limitation failure of human trials or rejection by medical regulators. The forward-looking statements in this document are made as of the date hereof and the Company disclaims any intent or obligation to update such forward-looking statements except as required by applicable securities laws.


PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Financialmorningpost.com, Joint Salty Holdings Corp., and their owners, managers, employees, and assigns (collectively, “we” or the “Company”) has been paid by the profiled company to disseminate this communication. In this case the Company has been paid by Champignon seven thousand US dollars per month for market awareness including postings and articles. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by Champignon to conduct investor awareness advertising and marketing for [CSE:SHRM and OTC: SHRMTF]. Financialmorningpost.com receives financial compensation to promote public companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of SHRM. The profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.

SHARE OWNERSHIP. The owner of Financialmorningpost.com owns shares of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The owner of Financialmorningpost.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of Financialmorningpost.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

LEGAL ADVISORY. Investing in companies associated with the psychedelic medicine industry may be illegal in the jurisdiction where a reader resides. Before investing in any public company involved in the psychedelic medicine industry, potential investors should check with their legal advisor as to whether an investment will breach local or federal law.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

Back to homepage

Leave a comment

Leave a comment